[24] A total of 3386 patients have now completed 6-month follow-up. The combined stent thrombosis ... of the Optical Coherence Tomography Drug Eluting Stent Investigation (OCTDESI)trial; part ...

Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug ... To date, four major clinical trials have demonstrated the sirolimus-eluting stent to be safe ...

Sino Medical Sciences Technology Inc. received marketing approval from China’s NMPA for its drug eluting stent system to improve vascular stenosis in patients with localized ischemic heart disease.

Novel drug-coated balloons (DCB) did not outshine standard treatment with second generation drug-eluting stents (DES ... the ...

Drug-coated balloon (DCB) angioplasty as the initial strategy for de novo coronary artery stenoses didn't measure up to ...

The impact of overlap of drug-eluting stents ... long-term follow-up than patients with DES that do not overlap. However, while this analysis raises questions as to whether stent overlap has ...

The DynamX Bioadaptor device was noninferior to DES for TLF overall, but a landmark analysis reveals a potential strength.

A study has found that sirolimus-coated balloons vs thin drug-eluting stents in in-stent restenosis show similar favorable clinical outcomes.

The company's drug-eluting stent technologies have been developed through a technological collaboration with the prestigious ...

The trial was set up to give DCBs their “best shot” in this patient group, says one researcher, but it’s tough to beat current DES.